BUZZ-Emergent up on gaining commercial rights for Hikma's opioid overdose treatment

** Shares of drugmaker Emergent BioSolutions EBS.N rise ~2.9% to $9.68 premarket

** Emergent says it gained exclusive commercial rights to Hikma Pharmaceuticals' HIK.L opioid reversal nasal spray, Kloxxado

** Kloxxado rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose

** Under the terms of the agreement, Hikma will continue to manufacture the nasal spray, while Emergent will handle distribution

** Up to last close, EBS up more than four-fold in the last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))